These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 25998416)

  • 21. Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient.
    Glück S; Arteaga CL; Osborne CK
    Clin Cancer Res; 2011 Sep; 17(17):5559-61. PubMed ID: 21764887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications.
    Harbeck N
    Breast; 2015 Nov; 24 Suppl 2():S44-8. PubMed ID: 26321480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The potential markers of endocrine resistance among HR+ /HER2+ breast cancer patients.
    Chen K; Quan J; Yang J; Chen Z
    Clin Transl Oncol; 2020 Apr; 22(4):576-584. PubMed ID: 31209793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
    Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study.
    Tong LC; Nelson N; Tsourigiannis J; Mulligan AM
    Am J Surg Pathol; 2011 Apr; 35(4):545-52. PubMed ID: 21358301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implications of different CA 15-3 levels according to breast cancer subtype at initial diagnosis of recurrent or metastatic breast cancer.
    Park S; Ahn HK; Park LC; Hwang DW; Ji JH; Maeng CH; Cho SH; Lee JY; Park KT; Ahn JS; Park YH; Im YH
    Oncology; 2012; 82(3):180-7. PubMed ID: 22433564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hormone receptor status might be a determinant for HER2 loss after HER2-targeted treatment in HER2 positive breast cancer patients.
    Altundag K
    J BUON; 2019; 24(5):2206. PubMed ID: 31786897
    [No Abstract]   [Full Text] [Related]  

  • 30. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
    Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
    Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted Therapy for Premenopausal Women with HR
    Bardia A; Hurvitz S
    Clin Cancer Res; 2018 Nov; 24(21):5206-5218. PubMed ID: 29884743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
    Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
    Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
    Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
    Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hormone receptor and HER2 status: The only predictive factors of response to neoadjuvant chemotherapy in breast cancer.
    Baulies S; Cusidó M; González-Cao M; Tresserra F; Fargas F; Rodríguez I; Úbeda B; Ara C; Fábregas R
    J Obstet Gynaecol; 2015; 35(5):485-9. PubMed ID: 25383894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
    Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
    Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triple positive breast cancer: a distinct subtype?
    Vici P; Pizzuti L; Natoli C; Gamucci T; Di Lauro L; Barba M; Sergi D; Botti C; Michelotti A; Moscetti L; Mariani L; Izzo F; D'Onofrio L; Sperduti I; Conti F; Rossi V; Cassano A; Maugeri-Saccà M; Mottolese M; Marchetti P
    Cancer Treat Rev; 2015 Feb; 41(2):69-76. PubMed ID: 25554445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
    Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
    Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted therapy for triple-negative breast cancer: where are we?
    Duffy MJ; McGowan PM; Crown J
    Int J Cancer; 2012 Dec; 131(11):2471-7. PubMed ID: 22581656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic targets in triple negative breast cancer.
    O'Toole SA; Beith JM; Millar EK; West R; McLean A; Cazet A; Swarbrick A; Oakes SR
    J Clin Pathol; 2013 Jun; 66(6):530-42. PubMed ID: 23436929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effective therapeutic regimens for patients with triple-negative (ER/PgR/HER2-negative) metastatic breast cancer].
    Kan N; Kuwata K; Mise K; Kodama H
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1259-64. PubMed ID: 20647706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.